CN105106245A - Application of Akkermansia muciniphila BAA-835 bacterial strain - Google Patents
Application of Akkermansia muciniphila BAA-835 bacterial strain Download PDFInfo
- Publication number
- CN105106245A CN105106245A CN201510523076.7A CN201510523076A CN105106245A CN 105106245 A CN105106245 A CN 105106245A CN 201510523076 A CN201510523076 A CN 201510523076A CN 105106245 A CN105106245 A CN 105106245A
- Authority
- CN
- China
- Prior art keywords
- bacterial strain
- obesity
- akkermansiamuciniphilabaa
- mice
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the field of application of probiotics, and particularly relates to application of an Akkermansia muciniphila BAA-835 bacterial strain on preparation medicines for treating or preventing obesity. C57/BL6 male SPF-level mice in a nest are randomly divided into a comparison group and a bacteria intragastric administration group, according to a check experiment, an Akkermansia muciniphila BAA-835 bacterial strain suspension intragastric administration experiment is carried out on the mice of the bacteria intragastric administration group once every day, and lasts for 5 weeks, through the experiment, weight and body fat of the mice in the bacteria intragastric administration group are reduced obviously, and by the Akkermansia muciniphila BAA-835 bacterial strain, content of subcutaneous fat of groins of the mice and content of fat beside epididymides of the mice are reduced quite effectively, and therefore, the bacterial strain can be used for treating or preventing the obesity.
Description
Technical field
The invention belongs to the application of probiotic bacteria, particularly AkkermansiamuciniphilaBAA-835 bacterial strain is in treatment or the application in preventing obesity.
Background technology
The fat risk factors as type 2 diabetes mellitus, cardiovascular disease and tumor etc., become the social common problem in the harm whole world, past, whole-genome association found more than 100 human obesity susceptibility loci during the decade, but limited fat pathogenic factor only can be explained in these sites.Further, at present fat effective treatment means is also very limited, and the slimming medicine of U.S. FDA approval before, mostly because side effect is large or weak effect and quitting listing, suddenly must develop new fat-reducing means.And another genome of the mankind and intestinal microbial population genome---encoding gene is 150 times of mankind itself's genome encoding gene, this rich determine its may obesity occur in play the part of certain role.Research shows that adiposis patient intestinal microflora lack of proper care, and the decline of intestinal bacteria multiformity, exists the out of proportion of Bacteroidetes and Firmicutes; Find that some can reduce the bacteria types of body weight, as BacteroidesuniformisCECT77712 based on the research in Mice Body.This section of article adopts the administering mode of mouse stomach, on common C57BL6 mice High-fat diet basis, gives physiological saline solution or bacterial suspension respectively, every day gavage, continue 4-8 week, record body weight growth curve, detection bodies fat, blood glucose after off-test, leave and take serum and fatty tissue.Result shows that this antibacterial continues gavage and can resist obesity that high fat diet causes and body fat increases, and reduces blood glucose, improves whole body and fatty tissue inflammation.The exploitation probiotic bacteria intervention obesity that is found to be of these researchs provides important tests foundation and technological means.
Therefore this area is in the urgent need to developing a kind of medicine being used for the treatment of and preventing class obesity that is effective, new, that have no side effect.
Summary of the invention
The object of this invention is to provide AkkermansiamuciniphilaBAA-835 bacterial strain preparation treatment or in preventing obesity in application, relate to the application of the aspect such as medicine, pharmaceutical composition, food and feeds for the treatment of or preventing obesity.This bacterial strain reduces mouse blood sugar, improves the carbohydrate metabolism of mice.Widen the scope of application of AkkermansiamuciniphilaBAA-835 bacterial strain, the application developing a kind for the treatment of that is effective, new, that have no side effect and prevent obesity.
The present invention relates to the application of AkkermansiamuciniphilaBAA-835 bacterial strain in preparation treatment or prevention of obesity disease drug.Prove through experiment, AkkermansiamuciniphilaBAA-835 bacterial strain has reduction mouse blood sugar, improves the beneficial effect of glucose tolerance in mice, so, this bacterial strain is the probiotic bacteria that obesity is intervened, and can be applied in the medicine prepared and treat or prevent obesity.
Treatment or the pharmaceutical composition prevented obesity, is characterized in that, comprising: AkkermansiamuciniphilaBAA-835 bacterial strain and pharmaceutically acceptable adjuvant.Preferably, when this treatment or the pharmaceutical composition prevented obesity are solid-state, in described pharmaceutical composition, 10 are comprised
7-10
12the AkkermansiamuciniphilaBAA-8352 bacterial strain of cfu/g;
When this treatment or the pharmaceutical composition prevented obesity are liquid, in described pharmaceutical composition, comprise 10
7-10
11the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
Described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.Through zoopery, this pharmaceutical composition can be treated or prevent obesity.
The medicine that aforementioned pharmaceutical compositions can be prepared into treatment or prevent obesity.Preferably, described medicine is at least one dosage form in granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.
Treatment or the food prevented obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and bromatology.Preferably, when described treatment or the food prevented obesity are solid-state, in described food, 10 are comprised
7-10
12the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g;
When this treatment or the food prevented obesity are liquid, in described food, comprise 10
7-10
11the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
In described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
Treatment or the feedstuff prevented obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and feedstuff.
Beneficial effect of the present invention is: the invention provides the novelty teabag of AkkermansiamuciniphilaBAA-835 bacterial strain in preparation treatment or prevention of obesity disease drug, by experiment, demonstrating AkkermansiamuciniphilaBAA-835 bacterial strain controls very effective to body weight and body fat, and the groin subcutaneous fat content of Guan Junzu group reduces 38.4%, the other fat content of epididymis of Guan Junzu group reduces 31.7%, illustrate that the reduction effect of Akkermansiamuciniphila bacterial strain to groin subcutaneous fat content and the other fat content of epididymis is very effective.So, medicine, pharmaceutical composition that AkkermansiamuciniphilaBAA-835 bacterial strain may be used for treating or prevent obesity, in food and feeds, widen the application of AkkermansiamuciniphilaBAA-835 bacterial strain.
Accompanying drawing explanation
Fig. 1 is that mice fills with bacterium after 5 weeks, body weight increased percentage comparison diagram.
Fig. 2 is that mice fills with bacterium after 5 weeks, body fat percentage of liveweight percentage ratio comparison diagram.
Fig. 3 is that mice fills with bacterium after 5 weeks, adipose tissue mass percentage of liveweight percentage ratio comparison diagram.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described:
The mouse model used in the present embodiment is: choose C57/BL6 in 10 week age male SPF level mice, all buy from Shanghai Si Laike zoopery company limited.Mice 5 cages are raised in isolation bag, and feed of freely intaking, maintains circadian rhythm.
Bacterial strain information: AkkermansiamuciniphilaBAA-835 bacterial strain is bought from ATCC company of the U.S., name of product: Akkermansia
bAA-835.
Embodiment 1
Be divided into matched group at random by brood for male for C57/BL6 SPF level mice and fill with bacterium group, only often organize 8-10, matched group gives aseptic PBS gavage, once a day; Fill with bacterium group and give AkkermansiamuciniphilaBAA-835 strain suspensions according to 2*10
9cfu/ mice, carries out gavage test, once a day.Test 5 weeks.Period records Mouse Weight rate of increase, detects the lipid metabolism related levels such as fat content after off-test.
Body weight and body fat situation are as shown in following table 1.
Table 1
As can be seen from the table, after AkkermansiamuciniphilaBAA-835 strain suspensions gavage is carried out to mice, body weight and body fat obviously increase slowly than the mice of matched group, illustrate that the control of AkkermansiamuciniphilaBAA-835 bacterial strain to body weight and body fat is very effective.Specifically as depicted in figs. 1 and 2.
The groin subcutaneous fat content of mice and the other fat content of epididymis are tested, possess shown in table 2:
Table 2
As can be seen from Table 2, after giving mice Akkermansiamuciniphila strain suspensions gavage, the groin subcutaneous fat content of Guan Junzu group reduces 38.4%, the other fat content of epididymis of Guan Junzu group reduces 31.7%, illustrates that the reduction effect of Akkermansiamuciniphila bacterial strain to groin subcutaneous fat content and the other fat content of epididymis is very effective.Specifically as shown in Figure 3.
The above is preferred embodiment of the present invention, but the present invention should not be confined to the content disclosed in this embodiment.The equivalence completed under not departing from spirit disclosed in this invention so every or amendment, all fall into the scope of protection of the invention.
Claims (10)
- The application of 1.AkkermansiamuciniphilaBAA-835 bacterial strain in preparation treatment or prevention of obesity disease drug.
- 2. the pharmaceutical composition for the treatment of or preventing obesity, is characterized in that, comprising: AkkermansiamuciniphilaBAA-835 bacterial strain and pharmaceutically acceptable adjuvant.
- 3. treatment according to claim 2 or the pharmaceutical composition that prevents obesity, is characterized in that: when this pharmaceutical composition is solid-state, comprise 10 in described pharmaceutical composition 7-10 12the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this pharmaceutical composition is liquid, in described pharmaceutical composition, comprise 10 7-10 11the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
- 4. treatment according to claim 3 or the pharmaceutical composition that prevents obesity, it is characterized in that, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
- 5. the medicine for the treatment of or preventing obesity, is characterized in that, comprise the pharmaceutical composition any one of claim 2-4.
- 6. treatment according to claim 5 or the medicine that prevents obesity, it is characterized in that, described medicine is at least one dosage form in granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.
- 7. the food for the treatment of or preventing obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and bromatology.
- 8. treatment according to claim 7 or the food that prevents obesity, is characterized in that, when described food is solid-state, comprise 10 in described food 7-10 12the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this food is liquid, in described food, comprise 10 7-10 11the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
- 9. treatment according to claim 7 or the food that prevents obesity, it is characterized in that, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
- 10. the feedstuff for the treatment of or preventing obesity, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and feedstuff.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510523076.7A CN105106245A (en) | 2015-08-24 | 2015-08-24 | Application of Akkermansia muciniphila BAA-835 bacterial strain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510523076.7A CN105106245A (en) | 2015-08-24 | 2015-08-24 | Application of Akkermansia muciniphila BAA-835 bacterial strain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106245A true CN105106245A (en) | 2015-12-02 |
Family
ID=54654527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510523076.7A Pending CN105106245A (en) | 2015-08-24 | 2015-08-24 | Application of Akkermansia muciniphila BAA-835 bacterial strain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106245A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486487B2 (en) | 2014-10-31 | 2016-11-08 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| CN110638838A (en) * | 2018-06-26 | 2020-01-03 | 深圳月曜生命科技有限公司 | Application of Ackermansia or prevotella in preparing medicine for enhancing anti-tumor immunity |
| WO2020063646A1 (en) * | 2018-09-27 | 2020-04-02 | 上海上药信谊药厂有限公司 | Strain for preventing and treating metabolic diseases and use thereof |
| CN111321089A (en) * | 2018-12-17 | 2020-06-23 | 上海究本科技有限公司 | Murine Akkermansia muciniphila 139 strain and application thereof |
| CN111450233A (en) * | 2020-03-19 | 2020-07-28 | 中国农业大学 | Application of microbial metabolite in relieving glycolipid metabolic disorder |
| CN111450124A (en) * | 2019-01-18 | 2020-07-28 | 深圳月曜生命科技有限公司 | Application of Achimbe or prevotella in medicine for increasing tumor microenvironment gamma T cell accumulation and enhancing anti-tumor immune function |
| CN113322202A (en) * | 2021-05-31 | 2021-08-31 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| JP2022502006A (en) * | 2019-08-23 | 2022-01-11 | エンテロバイオーム インコーポレイテッドEnterobiome Inc. | Akkermansia muciniphila EB-AMDK19 strain and its use |
| JP2022502005A (en) * | 2019-08-23 | 2022-01-11 | エンテロバイオーム インコーポレイテッドEnterobiome Inc. | Akkermansia muciniphila EB-AMDK27 strain and its use |
| CN114832019A (en) * | 2022-06-08 | 2022-08-02 | 广州知易生物科技有限公司 | Application of akkermansia muciniphila in preparation of pharmaceutical composition for preventing and treating obesity, composition and application thereof |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014076246A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
-
2015
- 2015-08-24 CN CN201510523076.7A patent/CN105106245A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014076246A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
Non-Patent Citations (2)
| Title |
|---|
| AMANDINE EVERARD等: "Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity", 《PNAS》 * |
| MARIA CARLOTA DAO等: "Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology", 《GUT》 * |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590176B2 (en) | 2012-02-29 | 2023-02-28 | Johnson & Johnson Consumer Inc. | Compositions of microbiota and methods related thereto |
| US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10729732B2 (en) | 2012-02-29 | 2020-08-04 | Ethicon Endo Surgery, Inc. | Compositions of microbiota and methods related thereto |
| US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US9486487B2 (en) | 2014-10-31 | 2016-11-08 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| CN110638838A (en) * | 2018-06-26 | 2020-01-03 | 深圳月曜生命科技有限公司 | Application of Ackermansia or prevotella in preparing medicine for enhancing anti-tumor immunity |
| CN110638838B (en) * | 2018-06-26 | 2021-07-06 | 瑞微（深圳）生物科技有限公司 | Application of Ackermansia or prevotella in preparing medicine for enhancing anti-tumor immunity |
| WO2020063646A1 (en) * | 2018-09-27 | 2020-04-02 | 上海上药信谊药厂有限公司 | Strain for preventing and treating metabolic diseases and use thereof |
| CN111321089A (en) * | 2018-12-17 | 2020-06-23 | 上海究本科技有限公司 | Murine Akkermansia muciniphila 139 strain and application thereof |
| CN111321089B (en) * | 2018-12-17 | 2022-03-15 | 上海究本科技有限公司 | Murine Akkermansia muciniphila 139 strain and application thereof |
| CN111450124B (en) * | 2019-01-18 | 2022-03-15 | 瑞微（深圳）生物科技有限公司 | Application of Achimbe or prevotella in medicine for increasing tumor microenvironment gamma delta T cell accumulation and enhancing anti-tumor immune function |
| CN111450124A (en) * | 2019-01-18 | 2020-07-28 | 深圳月曜生命科技有限公司 | Application of Achimbe or prevotella in medicine for increasing tumor microenvironment gamma T cell accumulation and enhancing anti-tumor immune function |
| JP2022502005A (en) * | 2019-08-23 | 2022-01-11 | エンテロバイオーム インコーポレイテッドEnterobiome Inc. | Akkermansia muciniphila EB-AMDK27 strain and its use |
| JP7055521B2 (en) | 2019-08-23 | 2022-04-18 | エンテロバイオーム インコーポレイテッド | Akkermansia muciniphila EB-AMDK19 strain and its use |
| JP7055520B2 (en) | 2019-08-23 | 2022-04-18 | エンテロバイオーム インコーポレイテッド | Akkermansia muciniphila EB-AMDK27 strain and its use |
| JP2022502006A (en) * | 2019-08-23 | 2022-01-11 | エンテロバイオーム インコーポレイテッドEnterobiome Inc. | Akkermansia muciniphila EB-AMDK19 strain and its use |
| CN111450233A (en) * | 2020-03-19 | 2020-07-28 | 中国农业大学 | Application of microbial metabolite in relieving glycolipid metabolic disorder |
| CN113322202B (en) * | 2021-05-31 | 2022-03-01 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| CN113322202A (en) * | 2021-05-31 | 2021-08-31 | 君维安(武汉)生命科技有限公司 | Ackermanella, culture method and application thereof |
| CN114832019A (en) * | 2022-06-08 | 2022-08-02 | 广州知易生物科技有限公司 | Application of akkermansia muciniphila in preparation of pharmaceutical composition for preventing and treating obesity, composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105106245A (en) | Application of Akkermansia muciniphila BAA-835 bacterial strain | |
| DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
| Jones | Probiotics: Preventing Antibiotic‐Associated Diarrhea | |
| US11141400B2 (en) | Method of treatment | |
| US20150037286A1 (en) | Use of roseburia in the prevention and treatment for obesity related diseases | |
| CN105030841A (en) | Application of Akkermansia muciniphila BAA-835 strain | |
| CN108348536B (en) | Synthetic compositions for treating antibiotic-associated complications | |
| US20050058671A1 (en) | Dietary supplement and method for treating digestive system-related disorders | |
| WO2023116227A1 (en) | Microbial combination having weight loss effect and application thereof | |
| Alkizim et al. | Childhood diarrhoea: failing conventional measures, what next? | |
| CN109419817B (en) | Use of parabacteroides goehrlii for reducing insulin resistance and improving glucose tolerance | |
| AU7687091A (en) | Antidiarrheal composition and method | |
| CN105106243A (en) | Application of Bacteroides thetaiotaomicron VPI-5482 in preparation of pharmaceuticals for treating or preventing obesity | |
| JP7370321B2 (en) | Methods for maintaining and improving renal function in patients with renal disease and receiving standard of care treatments | |
| Rogovik et al. | Treating infants' colic. | |
| CN109999019B (en) | Application of myristoleic acid methyl ester in preparation of product for preventing or treating metabolic syndrome or improving body energy metabolism | |
| CN105030842A (en) | Application of bacteroides intestinalis DSM 17393 strain | |
| DE102008059070A1 (en) | Composition, useful for therapeutic or prophylactic treatment of diarrhea and to maintain the natural intestinal flora comprises combination of microorganisms that positively influence the intestinal flora and a prebiotic | |
| CN110448569B (en) | Composition with antidiarrheal effect, preparation method and application thereof | |
| WO2022090335A1 (en) | Direct delivery of vitamins to rebalance gut microbiome after exposure to antibiotics | |
| CN105194658A (en) | Traditional Chinese medicinal preparation for treating obesity and enhancing physique and preparation method of traditional Chinese medicinal preparation | |
| US20170056459A1 (en) | Compositions and Methods for Aiding Phase 3 Recovery After Anesthesia | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product | |
| JP6856813B1 (en) | Zinc Intravenous Infusion Formulation | |
| CA3116039C (en) | Human dietary supplement and method for treating digestive system and immune-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |